MX356797B - Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro. - Google Patents

Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.

Info

Publication number
MX356797B
MX356797B MX2014005378A MX2014005378A MX356797B MX 356797 B MX356797 B MX 356797B MX 2014005378 A MX2014005378 A MX 2014005378A MX 2014005378 A MX2014005378 A MX 2014005378A MX 356797 B MX356797 B MX 356797B
Authority
MX
Mexico
Prior art keywords
alpha
synuclein
brain
diagnose
elevated level
Prior art date
Application number
MX2014005378A
Other languages
English (en)
Other versions
MX2014005378A (es
Inventor
Weihofen Andreas
Grimm Jan
Engber Thomas
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MX2014005378A publication Critical patent/MX2014005378A/es
Publication of MX356797B publication Critical patent/MX356797B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a el uso de un anticuerpo anti-a-sinucleino para diagnosticar un nivel elevado de a-sinucleino en el cerebro. Específicamente, la descripción se relaciona con el método para valorar los niveles de a-sinucleina en el plasma sanguíneo o CFS después de la administración del sujeto de prueba del anticuerpo anti-a-sinucleíno o fragmento de enlace del antígeno del mismo, el cual puede enlazar la a-sinucleina del cerebro a la sangre o del cerebro a CSF.
MX2014005378A 2011-11-02 2012-10-29 Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro. MX356797B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (2)

Publication Number Publication Date
MX2014005378A MX2014005378A (es) 2015-01-19
MX356797B true MX356797B (es) 2018-06-14

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005378A MX356797B (es) 2011-11-02 2012-10-29 Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.

Country Status (14)

Country Link
US (3) US20140295465A1 (es)
EP (1) EP2773957B1 (es)
JP (1) JP6263473B2 (es)
KR (1) KR102036938B1 (es)
CN (2) CN104040342A (es)
AU (1) AU2012332814B2 (es)
BR (1) BR112014010664A2 (es)
CA (1) CA2854131C (es)
EA (1) EA034213B1 (es)
HK (1) HK1201585A1 (es)
IL (1) IL232373B (es)
MX (1) MX356797B (es)
WO (1) WO2013066818A1 (es)
ZA (1) ZA201403879B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
CN110494445B (zh) * 2017-01-06 2023-10-20 Abl生物公司 抗α-SYN抗体及其用途
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
AU2018385230B2 (en) 2017-12-14 2022-10-13 Abl Bio Inc. Bispecific antibody to a-syn/IGF1R and use thereof
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
AU7186501A (en) * 2000-07-07 2002-01-21 Panacea Pharmaceuticals Inc Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
AU2008203703C1 (en) 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
JP5747414B2 (ja) * 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Also Published As

Publication number Publication date
IL232373B (en) 2018-08-30
IL232373A0 (en) 2014-06-30
EP2773957A1 (en) 2014-09-10
AU2012332814A1 (en) 2014-06-12
JP6263473B2 (ja) 2018-01-31
CN107091931A (zh) 2017-08-25
NZ625217A (en) 2016-07-29
KR20140095074A (ko) 2014-07-31
JP2014533357A (ja) 2014-12-11
US20180011112A1 (en) 2018-01-11
CN104040342A (zh) 2014-09-10
MX2014005378A (es) 2015-01-19
CA2854131C (en) 2020-07-07
US20190094245A1 (en) 2019-03-28
BR112014010664A2 (pt) 2017-04-25
AU2012332814B2 (en) 2017-12-14
ZA201403879B (en) 2018-11-28
EA201490883A1 (ru) 2014-10-30
EA034213B1 (ru) 2020-01-17
EP2773957B1 (en) 2017-11-29
US20140295465A1 (en) 2014-10-02
KR102036938B1 (ko) 2019-10-25
HK1201585A1 (en) 2015-09-04
CA2854131A1 (en) 2013-05-10
WO2013066818A1 (en) 2013-05-10
EP2773957A4 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
MX356797B (es) Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.
CY1122278T1 (el) Αντι il-36r αντισωματα
CR20130359A (es) Anticuerpos del cea
DK3378535T5 (da) Humanserede antistoffer, der genkender alpha-synuklein
MX2014014678A (es) Molecula de union al antigeno especifico para el tejido objetivo.
JO3625B1 (ar) بروتينات رابطة للأنتيجين cd27l
MA34091B1 (fr) Anticorps anti-cd40
EP2686446A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR MACULOPATHY AND SYMPTOMS THEREOF
MX362720B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
NZ707139A (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
PH12014502406B1 (en) Anti-il-23p19 antibodies
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
PH12014502399B1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
IN2012DN02521A (es)
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
WO2012166626A8 (en) Reagents and methods for treating dental disease
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
HUE038721T2 (hu) Javított diagnosztikus teszt CSFV antitestek számára
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2013049152A3 (en) Methods for evaluating lung cancer status
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
GB201114909D0 (en) Biomarkers for lysosomal storage disorders

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: HENKEL IP & HOLDING GMBH

FG Grant or registration